- More than 10 thousand people will be involved in the second phase of testing
- Testing is done on 1 thousand people in the first phase of testing
- ChAdOx1 nCoV-19 Vaccine Raises Hope
To overcome the epidemic caused by the Corona virus, work is going on fast on the discovery of vaccine worldwide. Meanwhile, researchers at the University of Oxford on Friday confirmed the initial success on the vaccine for the protection of the coronavirus, saying they are moving to another level of human testing.
Researchers at the University of Oxford are going to the next level, starting to recruit more than 10,000 people for the second phase of testing.
10,200 people in the second phase
The first phase of the trial on the vaccine began last month, in which 1,000 healthy adults and volunteers under age 55 were trialled. Now, to see the impact on their immune system, more than 10,200 people, including children over 70 years and 5 to 12 years old, will be enrolled for the study.
A recent study found that the vaccine named ChAdOx1 nCoV-19 has shown some promising results in small studies with monkeys.
Effect of vaccine
“The COVID-19 vaccine trial team is working hard to assess the safety and immunogenicity and vaccine efficacy of ChAdOx1 nCoV-19,” said Sarah Gilbert, professor of vaccineology at the University’s Jenner Institute.
He said that we are already very interested in people over the age of 55 who were not eligible to participate in the first phase of research, and now we will be able to include older age groups to continue vaccination. We will cover more parts of the country as well as more study sites.